Trevi Therapeutics (TRVI) Earnings Analysis

Trevi Therapeutics (TRVI) next reports earnings on 2026-08-06, consensus EPS -0.11 USD. Last quarter (2026-03-17) it beat with EPS -0.06 USD vs -0.1 USD est (+40%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -53.88.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TRVI next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.11 USD
Revenue estimaten/a

TRVI earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-17-0.06 USD-0.1 USD+40%Beat
2025-11-13-0.08 USD-0.1 USD+20%Beat
2025-08-07-0.09 USD-0.1 USD+10%Beat
2025-05-08-0.09 USD-0.13 USD+30.8%Beat
2025-03-18-0.11 USD-0.12 USD+8.3%Beat
2024-08-08-0.12 USD-0.11 USD-9.1%Miss

Beat rate: 5/6 (83%) over reported quarters with consensus data.

TRVI valuation and analyst view

Trailing P/E-53.88
Trailing EPS-0.31328 USD
Price / book14.68
Dividend yield0.00%
Market cap2.46B
Analyst consensusBuy (17 buy / 0 hold / 0 sell)
Avg price target27.5 USD

Related research pages

Frequently asked questions

When is Trevi Therapeutics (TRVI)'s next earnings date?

Trevi Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.11 USD.

Did TRVI beat earnings last quarter?

In its 2026-03-17 report, TRVI posted EPS of -0.06 USD versus a -0.1 USD estimate — a beat of 40%.

What is TRVI's earnings track record?

Over the last 6 reported quarters with consensus data, TRVI beat estimates 5 times (83%).

What is TRVI's current P/E ratio and EPS?

TRVI trades at a trailing P/E of -53.88 on trailing EPS of -0.31327763707380213 USD.

What do analysts rate TRVI?

Analyst consensus is "Buy" across 17 ratings (1 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 27.5 USD.